Beryl Drugs Complete Financial Statements
In FY2026, Beryl Drugs (BERLDRG) reported revenue ₹19 Cr, net profit ₹0 Cr and EPS ₹0.84. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see BERLDRG share price.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
BERLDRG Revenue, Net Profit & EBITDA — Year-on-Year Growth
BERLDRG YoY (March 2025 vs March 2026) — revenue -17.4%, net profit -100.0%, EBITDA -33.3%, expenses -15.0%. Also explore BERLDRG price trends to track price trends across different timeframes.
BERLDRG Income Statement — Revenue, EBITDA & Net Profit
Beryl Drugs revenue ₹19 Cr, EBITDA ₹2 Cr, net profit ₹0 Cr, EPS ₹0.84 (2026). Analyse BERLDRG promoter holding to track promoter, FII and institutional holdings.
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19 | 23 | 27 | 27 | 15 | 14 | 13 | 13 | 16 | 11 | 14 | 14 |
| Expenses | 17 | 20 | 25 | 25 | 14 | 13 | 12 | 12 | 14 | 11 | 13 | 13 |
| EBITDA | 2 | 3 | 3 | 2 | 1 | 2 | 1 | 1 | 2 | 0 | 1 | 1 |
| Operating Profit Margin % | 10.00% | 6.00% | 9.00% | 7.00% | 3.00% | 10.00% | 7.00% | 8.00% | 7.00% | -1.00% | 4.00% | 6.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 1 | 1 | -1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 1 | 1 | 1 | -1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Earnings Per Share (₹) | 0.84 | 1.14 | 1.52 | 1.51 | -1.30 | 0.47 | 0.09 | 1.16 | 1.96 | -0.88 | 0.33 | 0.17 |
BERLDRG Balance Sheet — Assets, Liabilities & Shareholders' Equity
BERLDRG total assets ₹15 Cr, total equity ₹10 Cr, total liabilities ₹ Cr (2026).
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 15 | 16 | 18 | 18 | 18 | 19 | 17 | 15 | 11 | 10 | 10 | 11 |
| Current Assets | 7 | 9 | 10 | 10 | 11 | 10 | 8 | 5 | 7 | 7 | 6 | 6 |
| Fixed Assets | 7 | 6 | 6 | 6 | 6 | 8 | 9 | 2 | 2 | 2 | 2 | 2 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 |
| Investments | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Other Assets | 0 | 10 | 11 | 11 | 12 | 11 | 8 | 6 | 8 | 8 | 8 | 8 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 1 | 2 | 3 | 3 | 2 | 3 | 3 | 2 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 10 | 10 | 9 | 8 | 7 | 8 | 8 | 8 | 7 | 6 | 7 | 7 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 5 | 4 | 4 | 3 | 2 | 3 | 3 | 2 | 2 | 1 | 2 | 1 |
BERLDRG Cash Flow Statement — Operating, Investing & Financing
Beryl Drugs operating cash flow ₹3 Cr, investing ₹0 Cr, financing ₹-2 Cr, net cash flow ₹1 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 3 | 1 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 |
| Investing Activities | 0 | -1 | -1 | 1 | 0 | -2 | -5 | 0 | 0 | 0 | 0 |
| Financing Activities | -2 | 0 | -1 | 0 | -1 | 2 | 2 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 0 | 1 |